Experiment 445685

Details

PropertyValue
Pharmacology
Administration routeIV INFUSION
OrganismEmpty organism
CitationKANTARJIAN,HM: BERAN,M: ELLIS,A: ZWELLING,L: O'BRIEN,S: CAZENAVE,L: KOLLER,C: RIOS,MB: PLUNKETT,W: KEATING,MJ: ESTEY,EH:. (1993). PHASE I STUDY OF TOPOTECAN, A NEW TOPOISOMERASE I INHIBITOR, IN PATIENTS WITH REFRACTORY OR RELAPSED ACUTE LEUKEMIA.. 81(5)
Amount utilized
Compound isolated
Disease27 PATIENTS WITH REFRACTORY OR RELAPSED ACUTE LEUKEMIA WERE USED IN THIS PHASE 1 STUDY. THE PATIENTS WERE DOSED EVERY 3-4 WEEKS BY CONTINOUS 5 DAY INFUSION. THE DOSE LIMITING TOXICITY WAS SEVERE MUCOSISTIS. NAUSEA, VOMITING, DIARRHEA AND PROLONGED MYELOSUPPRESISON WERE UNCOMMON. 11% OF THE PATIENTS ACHIEVED A COMPLETE RESPONSE, 7% SHOWED A PARTIAL RESPONSE AND 4% SHOWED HEMATOLOGIC IMPROVEMENT. THE OVERALL COMPLETE AND PARTIAL RESPONSE WAS 19% AND 24% ACUTE MYELOGENOUS OR UNDIFFERENTIATED LEUKEMIA.
Dose amountVAR
Number1
Qualitative result.
AnimalHUMAN ADULT
Dose expressionDOSE